Publication: Rate of and predicting factors for virologic failure in HIV-infected patients with persistent low-level viremia under antiretroviral therapy
Issued Date
2015-01-01
Resource Type
ISSN
23259582
23259574
23259574
Other identifier(s)
2-s2.0-84921329084
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the International Association of Providers of AIDS Care. Vol.14, No.1 (2015), 12-16
Suggested Citation
Sastra Charuratananon, Somnuek Sungkanuparph Rate of and predicting factors for virologic failure in HIV-infected patients with persistent low-level viremia under antiretroviral therapy. Journal of the International Association of Providers of AIDS Care. Vol.14, No.1 (2015), 12-16. doi:10.1177/2325957414527168 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/36138
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Rate of and predicting factors for virologic failure in HIV-infected patients with persistent low-level viremia under antiretroviral therapy
Author(s)
Other Contributor(s)
Abstract
© The Author(s) 2014. To determine the rate of and predicting factors for virologic failure among HIV-infected patients with persistent low-level viremia (PLV) under antiretroviral therapy (ART), a retrospective cohort study was conducted among HIV-infected patients who experienced PLV under ART. Persistent low-level viremia was defined as HIV RNA level at 50 to 1000 copies/mL for at least 2 consecutive visits. Of 68 patients, mean ± standard deviation age was 35.2 ± 9.0 years and 64.7% were males. Median (interquartile range [IQR]) CD4 count was 94 (26-264) cells/mm3 and baseline HIV RNA was 112 000 (1 090-461 500) copies/mL. During the median (IQR) follow-up period of 5.7 (3.4-10.3) years of ART, the rate of virologic failure was 38.2%. In multivariate analyses, only maximum amplitude of HIV RNA >400 copies/mL during PLV (hazard ratio = 5.668; 95% confidence interval, 1.888-17.014; P =.002) significantly predicted virologic failure. Patients with PLV >400 copies/mL are more likely to develop virologic failure and should be closely monitored. Interventional studies to prevent virologic failure in these patients are needed.